Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Verbesserung der Knöchel-Plantarflexor-Funktion bei Zerebralparese

10. November 2026 aktualisiert von: Northern Arizona University

Verbesserung der Funktion des Knöchel-Plantarflexors und der Gehfähigkeit bei Kindern mit Zerebralparese

The first specific aim is to quantify improvement in ankle muscle function and functional mobility following targeted ankle resistance gait training in ambulatory children with cerebral palsy (CP). The primary hypothesis for the first aim is that targeted ankle resistance training will produce larger improvements in lower-extremity motor control, gait mechanics, and clinical measures of mobility assessed four- and twelve-weeks post intervention compared to standard physical therapy and standard gait training. The second specific aim is to determine the efficacy of adaptive ankle assistance to improve capacity and performance during sustained, high-intensity, and challenging tasks in ambulatory children with CP. The primary hypothesis for the second aim is that adaptive ankle assistance will result in significantly greater capacity and performance during the six-minute-walk-test and graded treadmill and stair stepping protocols compared to walking with ankle foot orthoses and walking with just shoes.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

A child's ability to walk effectively is essential to their physical health and general well-being. Unfortunately, many children with cerebral palsy (CP), the most common cause of pediatric physical disability, have difficulty walking and completing higher-intensity ambulatory tasks. This leads to children with CP engaging in levels of habitual physical activity that are well below guidelines and those of children without disabilities, which in turn contributes to many secondary conditions, including metabolic dysfunction and cardiovascular disease. There is broad clinical consensus that plantarflexor dysfunction is a primary contributor to slow, inefficient, and crouched walking patterns in CP; individuals with CP need more effective treatments and mobility aids for plantarflexor dysfunction. To meet this need, this proposal aims to evaluate a holistic strategy to address impaired mobility from plantarflexor dysfunction in CP using a lightweight, dual-mode (assistive or resistive) wearable robotic device. This strategy combines two complementary techniques: (1) targeted ankle resistance for neuromuscular gait training that provides precision therapy to elicit long-term improvements in ankle muscle function, and (2) adaptive ankle assistance to make walking easier during sustained, high-intensity, or challenging tasks.

Aim 1: Quantify improvement in ankle muscle function and functional mobility following targeted ankle resistance gait training in ambulatory children with CP Approach - Repeated Measures (RM) and randomized controlled trial: The investigators will compare functional outcomes following targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard physical therapy (RM) and vs. dose-matched standard treadmill training (randomized controlled trial). Primary Hypothesis: Targeted ankle resistance training will produce larger improvements in lower-extremity motor control, gait mechanics, and clinical measures of mobility assessed four- and twelve-weeks post intervention compared to the control conditions.

Aim 2: Determine the efficacy of adaptive ankle assistance to improve capacity and performance during sustained, high-intensity, and challenging tasks in ambulatory children with CP Approach - Repeated Measures: The investigators will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid) during (a) 6-minute-walk-test, (b) extended-duration over-ground walking (sustained), (c) graded treadmill (high-intensity), and (d) stair-stepping (challenging) protocols. Task capacity and performance will be measured by duration, metabolic cost, speed, and stride length, as applicable. Primary Hypothesis: Adaptive ankle assistance will result in significantly greater capacity and performance compared to the control conditions.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

36

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55101
        • Gillette Children's Specialty Healthcare

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

8 Jahre bis 21 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Ages between 8 and 21 years old, inclusive. Diagnosis of CP and a pathological gait pattern caused by ankle dysfunction.
  • Able to understand and follow simple directions (based on parent report, if needed) and walk at least 30 feet with or without a walking aid (Gross Motor Function Classification System (GMFCS) Level I-III).
  • At least 20° of passive plantar-flexion range of motion.

Exclusion Criteria:

  • Concurrent treatment other than those assigned during the study.
  • A condition other than CP that would affect safe participation.
  • Surgical intervention within 6 months of participation.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Device resisted gait training (treatment)

We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.

A lightweight resistive wearable ankle robotic device.

Experimental: Standard gait training (control)

We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.

Standard gait training without a device.

Experimental: Comparison to Standard PT (within subjects control)

We will use a within-subject repeated measures design to compare both gait training groups to matched standard physical therapy.

Physical therapy without a device.

Experimental: Device assisted ambulation

We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).

A lightweight assistive wearable ankle robotic device.

Experimental: Passive brace assisted ambulation

We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).

Standard ankle foot orthosis

Experimental: No ankle aid ambulation

We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).

Walking without a device

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in preferred walking speed
Zeitfenster: Immediately after the intervention

Participant's preferred walking speed compared after to before the intervention

Immediately after the intervention
Change in preferred walking speed
Zeitfenster: 2 weeks after the intervention

Participant's preferred walking speed compared after to before the intervention

2 weeks after the intervention
Change in preferred walking speed
Zeitfenster: 12 weeks after the intervention

Participant's preferred walking speed compared after to before the intervention

12 weeks after the intervention
Change in similarity of plantarflexor muscle activity
Zeitfenster: Immediately after the intervention

Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity.

Immediately after the intervention
Change in similarity of plantarflexor muscle activity
Zeitfenster: 2 weeks after the intervention

Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity.

2 weeks after the intervention
Change in similarity of plantarflexor muscle activity
Zeitfenster: 12 weeks after the intervention

Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity.

12 weeks after the intervention
Change in 6-minute-walk-test distance
Zeitfenster: Immediately after the intervention

Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity.

Immediately after the intervention
Change in 6-minute-walk-test distance
Zeitfenster: 2 weeks after the intervention

Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity.

2 weeks after the intervention
Change in 6-minute-walk-test distance
Zeitfenster: 12 weeks after the intervention

Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity.

12 weeks after the intervention
Change in variance in muscle activity
Zeitfenster: Immediately after the intervention

Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control.

Immediately after the intervention
Change in variance in muscle activity
Zeitfenster: 2 weeks after the intervention

Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control.

2 weeks after the intervention
Change in variance in muscle activity
Zeitfenster: 12 weeks after the intervention

Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control.

12 weeks after the intervention
Change in stride length
Zeitfenster: Immediately after the intervention

Participant stride length during walking. Longer stride length is desired.

Immediately after the intervention
Change in stride length
Zeitfenster: 2 weeks after the intervention

Participant stride length during walking. Longer stride length is desired.

2 weeks after the intervention
Change in stride length
Zeitfenster: 12 weeks after the intervention

Participant stride length during walking. Longer stride length is desired.

12 weeks after the intervention
Change in stride-to-stride variability stride length
Zeitfenster: Immediately after the intervention

Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides.

Immediately after the intervention
Change in stride-to-stride variability stride length
Zeitfenster: 2 weeks after the intervention

Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides.

2 weeks after the intervention
Change in stride-to-stride variability stride length
Zeitfenster: 12 weeks after the intervention

Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides.

12 weeks after the intervention
Change in walking posture
Zeitfenster: Immediately after the intervention

Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool).

Immediately after the intervention
Change in walking posture
Zeitfenster: 2 weeks after the intervention

Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool).

2 weeks after the intervention
Change in walking posture
Zeitfenster: 12 weeks after the intervention

Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool).

12 weeks after the intervention
Change in Gross Motor Function Measure-66 sec. D&E
Zeitfenster: Immediately after the intervention

Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure.

Immediately after the intervention
Change in Gross Motor Function Measure-66 sec. D&E
Zeitfenster: 2 weeks after the intervention

Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure.

2 weeks after the intervention
Change in Gross Motor Function Measure-66 sec. D&E
Zeitfenster: 12 weeks after the intervention

Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure.

12 weeks after the intervention
Change in plantar-flexor strength
Zeitfenster: Immediately after the intervention

Plantar-flexor muscle strength measured via hand-held dynamometry.

Immediately after the intervention
Change in plantar-flexor strength
Zeitfenster: 2 weeks after the intervention

Plantar-flexor muscle strength measured via hand-held dynamometry.

2 weeks after the intervention
Change in plantar-flexor strength
Zeitfenster: 12 weeks after the intervention

Plantar-flexor muscle strength measured via hand-held dynamometry.

12 weeks after the intervention
Distance traveled
Zeitfenster: 1 day

Distance traveled during the 6-minute-walk-test, and treadmill and stair stepper bruce protocols.

1 day
Metabolic cost of transport from indirect calorimetry
Zeitfenster: 1 day

Metabolic cost estimated from a wearable indirect calorimetry system during the 6-minute-walk-test, and treadmill and stair stepper bruce protocols

1 day
Subject perceived exertion
Zeitfenster: 1 day

Subject perceived exertion (validated pictorial pediatric exertion scale). The scale is from 1-10, where a higher number indicates more effort.

1 day
Average muscle activity
Zeitfenster: 1 day

Average stance-phase plantar flexor muscle activity assessed through surface electromyography of the soleus muscle.

1 day
Heart Rate
Zeitfenster: 1 day

Average heart rate during each testing condition measured via chest-mounted heart rate monitor.

1 day

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Zach F Lerner, PhD, Northern Arizona University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Februar 2023

Primärer Abschluss (Tatsächlich)

14. September 2026

Studienabschluss (Tatsächlich)

25. September 2026

Studienanmeldedaten

Zuerst eingereicht

13. Oktober 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

30. November 2021

Zuerst gepostet (Tatsächlich)

13. Dezember 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • 1R01HD107277 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .